top of page

Using a covalent menin inhibitor as an approach against diabetes (and more) with Biomea Fusion's CEO

Thomas Butler describes Biomea's hypothesis of utilizing a covalent, irreversible menin inhibitor to promote beta cell proliferation in diabetes. He reviews Biomea's latest clinical data, and highlights the company's cancer programs.


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight


Breakthrough Properties is a life science real estate company that is exclusively focused on delivering cutting-edge environments for the life science industry. With a portfolio of roughly 5 million square feet across the US, UK and continental Europe, Breakthrough has emerged as a leading partner for high-growth biotechs and pharmas around the world. 

bottom of page